Effects of ipratropium bromide combined with montelukast sodium on asthma and lung function in children

Abstract

Objective To investigate the efficacy of ipratropium bromide combined with montelukast sodium on pediatric asthma and its influence on pulmonary function. Methods A total of 100 cases of children with asthma hospitalized in Binzhou Central Hospital from April 2017 to October 2018 were selected and randomly divided into two groups. Children in control group were treated with montelukast sodium, and children in study group were treated with ipratropium bromide and montelukast sodium. The clinical efficacy of the two groups and the changes of pulmonary function indexes before and after treatment were observed and compared. Results The curative effect of study group was better than that of control group (P<0.05). After treatment, forced expiratory volume in one second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF) and FEV1/FVC were significantly increased in the both groups (P<0.05). After treatment, FEV1, FVC, PEF and FEV1/FVC in study group were higher than those in control group (P<0.05). Levels of IgE and interleukin-5(IL-5) were significantly decreased and interleukin -10(IL-10) level was significantly increased in the two groups (P<0.05). Levels of IgE and IL-5 in study group were lower than those in control group, and IL-10 level was higher in study group than control group (P<0.05). Conclusions The combined application of ipratropium bromide and montelukast sodium has a significant effect on pediatric asthma. The protolol can effectively relieve the clinical symptoms, improve the pulmonary function index and inflammatory factor level of the children with asthma, so it is worthy of application and promotion. Key words: Ipratropium bromide; Montelukast sodium; Infantile asthma; Curative effect; Lung function